Oarsman Capital’s Repligen RGEN Stock Holding History

Oarsman Capital’s Portfolio RGEN Stock Details RGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-604	Closed	-$86.9K	–	694
2024 Q4	$86.9K	Sell	604 -81	-12%	-$11.6K	0.02%	358
2024 Q3	$102K	Buy	+685	New	+$98.2K	0.02%	337

Other funds holding RGEN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $3.89B AUM 16.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Oarsman Capital's RGEN Position: Q1 2025 in Review

Oarsman Capital sold out of Repligen (RGEN) in Q1 2025, closing a stake of 604 shares — an estimated $86.9K sold.

Oarsman Capital first reported a position in RGEN in Q3 2024 and held it in 2 quarters. The position peaked at $102K in Q3 2024. 442 funds tracked by Wall St. Rank hold RGEN as of Q1 2025.

Oarsman Capital reported no remaining Repligen position as of Q1 2025 after selling out during the quarter.
Oarsman Capital sold 604 Repligen shares in Q1 2025, an estimated $86.9K.
Oarsman Capital first reported a position in Repligen in Q3 2024 and held it in 2 quarters.
Oarsman Capital's Repligen position peaked at $102K in Q3 2024.
442 funds tracked by Wall St. Rank held Repligen as of Q1 2025.

Based on Oarsman Capital's 13F filing for Q1 2025, filed 14 May 2025.